Wikipedia -WSS

Wikipedia

author：entertainment 2025-09-28 02:27:07 - browse：55

KalVista Pharmaceuticals said Tuesday that its oral, on-demand treatment for the swelling “attacks” commonly experienced by patients with a genetic condition called hereditary angioedema achieved the goals of a Phase 3 clinical trial.

Based on the study results, the company plans to submit a marketing application to the Food and Drug Administration by the middle of the year. Regulatory filings in Europe and Japan will be completed later in the year.

In the Phase 3 study involving 136 participants, a low and high dose of Kalvista’s drug, called sebetralstat, showed a median time to the beginning of symptom relief of 1.6 hours and 1.8 hours, respectively, compared to 6.7 hours for a placebo. The result was statistically significant and achieved the study’s main efficacy goal.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Anesthesiologist group: stop taking Ozempic before surgery
Next article： Apple is now the first public company to be valued at $3 trillion

leisure time

WSS

Tori Bowie and the unacceptable rates of Black maternal death

Ring Therapeutics, a Flagship gene therapy startup, lays off 20% of staff

DIEP, the 'gold standard' of breast reconstruction, is under threat

In 'major milestone,' FDA approves first cell therapy for solid tumors

Duchenne breakthrough therapy leaves behind pioneering families

A new drug could help frostbite victims avoid its ravages

leisure time

Wikipedia

explore

Medicare proposal to cover medical devices draws a mixed reaction

Hospitals are piloting generative AI tools as regulators play catch

State Dept. review finds Biden bears some blame for Afghanistan failures

Measles policy set amid Florida outbreak alarms vaccine proponents

How one medical school became remarkably diverse

Ukraine seeks to reclaim its role as a hub for clinical trials

Hepatitis C has a cure — but many Americans still lack access to it

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchenne breakthrough therapy leaves behind pioneering families

FDA warns medical device makers about rise in fabricated data

focus

New study raises questions about niacin and heart health

Abridge raises $150m as clinical notes automation market heats up

A new drug could help frostbite victims avoid its ravages

Novavax promises a turnaround & Lilly roils the obesity market

Measles policy set amid Florida outbreak alarms vaccine proponents

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

entertainment

leisure time

explore

hotspot